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Oriana Kreutzfeld*, Katja Müller * and Kai Matuschewski *
Department of Molecular Parasitology, Institute of Biology, Humboldt University, Berlin, Germany
Continuous stage conversion and swift changes in the antigenic repertoire in response
to acquired immunity are hallmarks of complex eukaryotic pathogens, including
Plasmodium species, the causative agents of malaria. Efficient elimination of Plasmodium
liver stages prior to blood infection is one of the most promising malaria vaccine
strategies. Here, we describe different genetically arrested parasites (GAPs) that have
been engineered in Plasmodium berghei, P. yoelii and P. falciparum and compare their
vaccine potential. A better understanding of the immunological mechanisms of prime and
boost by arrested sporozoites and experimental strategies to enhance vaccine efficacy
by further engineering existing GAPs into a more immunogenic form hold promise for
continuous improvements of GAP-based vaccines. A critical hurdle for vaccines that elicit
long-lasting protection against malaria, such as GAPs, is safety and efficacy in vulnerable
populations. Vaccine research should focus on solutions toward turning malaria into a
vaccine-preventable disease, which would offer an exciting new path of malaria control.
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INTRODUCTION
Malaria remains the most important vector-borne infectious disease and affects half of the world’s
population. Globally, >200 million infected individuals develop clinical symptoms, and >400,000
die because of severe malaria, primarily children in Sub-Saharan Africa (WHO, 2016a). New
strategies for malaria prevention and eradication are thus urgently required. The current malaria
control programs target the causative agents, Plasmodium falciparum, P. vivax, and three other
human-infecting Plasmodium parasites, at different life cycle stages, which together reduces
morbidity and mortality in endemic regions. Attacking the parasite at its vector stage with
long-lasting insecticide treated bed nets and insecticide-indoor residual spraying combined with
access to rapid diagnosis and artemisinin-based combination therapy for clinical malaria episodes
are recommended by the WHO (WHO, 2016a).
Abbreviations: β2M, β2 microglobulin; CAS, chemically arrested sporozoites; CSP, circumsporozoite protein; DC,
dendritic cell; ETRAMP, early transcribed membrane protein; FASII, fatty acid synthesis II; G3PAT, glycerol-3-phosphate
acyltransferase; G3PDH, glycerol-3-phosphate dehydrogenase; GAP, genetically arrested parasite; IK2, eukaryotic initiation
factor-2α kinase; MHC, major histocompatibility complex; PALM, Plasmodium-specific apicoplast protein important for liver
merozoite formation; PDH, pyruvate dehydrogenase; PKG, protein kinase G; PP1, eIF2α-P protein phosphatase 1; MSP1,
merozoite surface protein 1; PVM, parasitophorous vacuolemembrane; RAS, radiation attenuated sporozoites; SLARP/ SAP1,
sporozoite and liver stage asparagine-rich protein; TRAP, thrombospondin-related anonymous protein; UIS, upregulated in
infectious sporozoites.
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Repeated exposure to Plasmodium transmission in
malaria-endemic countries leads only to very slow acquisition of
naturally acquired immunity that rapidly wanes. Development
of protective immunity is likely hindered by blood infection,
the exclusive cause of malaria-related morbidity and mortality.
Therefore, the pre-erythrocytic phase of the Plasmodium
life cycle in the mammalian host is particularly attractive as
immunization agent since no clinical symptoms are associated
with this first replication phase (Prudêncio et al., 2006; Silvie
et al., 2008a; Matuschewski et al., 2011). It also allows priming
of CD4+ and CD8+ T cells by presenting parasite antigens to
the host immune system via MHCI and MHCII by dendritic
cells and MHCI by infected hepatocytes, respectively (Hafalla
et al., 2011). Prevention of disease by vaccination is an
ideal addition to the portfolio of malaria intervention tools;
however, it remains one of the greatest challenges in medical
research.
Approaches to design a protective long-lasting malaria
vaccine are wide-ranging, and some of them have already
reached clinical trial phases (WHO, 2016b). Among these
candidates is RTS,S/AS01, which is the first malaria vaccine
that achieved licensure for administration in malaria endemic
areas. RTS,S/AS01 is a hepatitis B-based subunit vaccine and
contains a fragment of the circumsporozoite protein (CSP)
(Stoute et al., 1997). Recent phase III clinical trial results revealed
an unfavorable protection level casting doubt on the impact
of RTS,S/AS01 in malaria control efforts (RTS,S Clinical Trials
Partnership, 2011; Olotu et al., 2016).
A benchmark for a malaria vaccine exists for several
decades already, and this experimental vaccine with proven
long-term protection is a whole sporozoite vaccine. Small
immunization studies in mice, non-human primates, and
humans demonstrated that radiation attenuated sporozoites
(RAS) elicit sterile protection against Plasmodium challenge
infections (Nussenzweig et al., 1967, 1969; Clyde et al., 1973;
Gwadz et al., 1979; Hoffman et al., 2002). Irradiation induces
DNA breakage in the parasites, which reduces the numbers
of nuclear divisions and limits liver stage expansion to early
schizonts (Silvie et al., 2002). Timing and radiation dosage
is critical since over-irradiated sporozoites arrest early at the
unicellular stage, thus decreasing protection in experimental
cohorts (Friesen andMatuschewski, 2011). Successful hepatocyte
invasion and initial intra-hepatic development of live,
metabolically active sporozoites are required to elicit strong
immunity, and, therefore, pose a substantial hurdle toward an
affordable and undemanding sporozoite vaccine. The central
importance of live and metabolically active sporozoites has
been corroborated with heat-killed sporozoites, which elicit
only very weak and short-term, antibody-mediated protection
against subsequent Plasmodium sporozoite challenge infections
(Hafalla et al., 2006). On the other hand, suboptimal irradiation
harbors the risk of breakthrough infections during vaccination—
a considerable drawback concerning safety. RAS arrest early
during liver stage development and express primarily sporozoite-
derived antigens, including CSP and thrombospondin-related
anonymous protein (TRAP), which likely contribute to priming
of T cell-mediated immunity.
Liver stage developmental arrest can also be achieved by an
alternative approach, termed chemical attenuation of sporozoites
(CAS), which is based on simultaneous administration of
normal sporozoites and anti-malarial drugs (Belnou et al., 2004;
Putrianti et al., 2009; Roestenberg et al., 2009; Friesen et al.,
2010; Bijker et al., 2013). While they offer interesting evaluations
in small-scale exploratory clinical studies, these approaches
are critically reliant on continuous clinical supervision during
drug administration and currently bear no translational
perspective.
The potential to induce lasting protection by live attenuated,
metabolically active parasites led to the engineering of genetically
attenuated parasites (GAPs) as tailored whole parasite vaccines
against malaria infections (Mueller et al., 2005a). Murine malaria
models employing the rodent malaria parasites P. berghei and
P. yoelii enable the exploration of liver stage-specific proteins and
their importance for parasite survival. In the past years, over 120
genes have been targeted by experimental genetics and analyzed
for defects during the Plasmodium life cycle in both vector
and mammalian host (Janse et al., 2011). Many gene knockouts
resulted in normal parasite life cycle progression or refractoriness
to targeted deletion, indicative of redundant functions during life
cycle progression or vital roles for blood infection, respectively.
Additionally, arrest of the parasite development in the mosquito
midgut, prior to salivary gland colonization, or ahead of
hepatocyte invasion was frequently observed. Accordingly, only
very few candidate genes fulfill the criteria of potential GAP
vaccine candidate lines (Table 1).
Herein, we review the most recent developments in GAP
vaccine discovery. We assess the different GAPs that have been
generated in the last 12 years and evaluate their vaccine potential.
Finally, we address the challenges and obstacles in designing
a GAP vaccine for vulnerable populations in malaria-endemic
countries.
FIRST GENERATION GAPs: PROOF OF
PRINCIPLE STUDIES
The first preclinical studies that showed successful generation
of GAP lines and their efficacy in immunization protocols
targeted Plasmodium berghei genes that represent members of the
early transcribed membrane protein (ETRAMP) family (Mueller
et al., 2005a,b). The selected genes, i.e., upregulated in infective
sporozoites gene 3 (UIS3) and UIS4, fulfilled three principal
criteria: (i) stage-specific gene expression in pre-erythrocytic
stages, thereby allowing recombinant knockout strains to be
selected during blood stage transfection; (ii) abundant expression
in pre-erythrocytic stages, indicating likely vital roles during
this phase of the life cycle; and (iii) genes that are unique to
Plasmodium and related haemosporidian parasites, which all
share the hallmark of the first obligate population expansion
phase in the host liver (Matuschewski et al., 2002). In vitro
studies in cultured hepatoma cells revealed that P. berghei
as well as P. yoelii 1UIS3 and 1UIS4 parasite lines arrest
early in liver stage development after completion of sporozoite
transformation to liver stages, but before onset of parasite
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TABLE 1 | Plasmodium genes targeted for GAPs. Plasmodium berghei (black), P. yoelii (green) and P. falciparum (blue) are listed.
Target gene Gene IDs Liver stage arrest Breakthroughs Referencesa
ETRAMPs/PV PROTEINS
UIS3 PBANKA_1400800 Early No Mueller et al., 2005a
PY17X_1402400 Early No Tarun et al., 2007
UIS4 PBANKA_0501200 Early Yes Mueller et al., 2005b
PY17X_0502200 Early No Tarun et al., 2007
6-CYS PROTEINS
P36, P36p (P52) PBANKA_1002100, Early Yes van Dijk et al., 2005,
PBANKA_1002200 Early Ishino et al., 2005
PY17X_1003500, Early No Labaied et al., 2007
PY17X_1003600 Early
PF3D7_0404400, Early Yes van Schaijk et al., 2008
PF3D7_0404500 Early
B9 PBANKA_0808100 Early Yes Annoura et al., 2014
PF3D7_0317100 Early Yes van Schaijk et al., 2014a
DIFFERENTIATION FACTORS
SLARP (SAP1) PBANKA_ 090210 Early No Silvie et al., 2008b
PY17X_0903500 Early No Aly et al., 2008
PF3D7_1147000 Early No van Schaijk et al., 2014a
METABOLISM
FabI PBANKA_1229800 Late Yes Yu et al., 2008
FabB/F PBANKA_1125100 Late Yes Annoura et al., 2012
PY17X_1126500 Late No Vaughan et al., 2009
FabZ PY17X_1342900 Late No Vaughan et al., 2009
G3PAT PBANKA_1416700 Late Yes Shears et al., 2017
PY17X_1418400 Late No Lindner et al., 2014
G3PDH PY17X_0934900 Late No Lindner et al., 2014
PDH-E1a PBANKA_0923800 Late Yes Nagel et al., 2013
PY17X_0925800 Late No Pei et al., 2010
PDH-E3 PY17X_0715100 Late No Pei et al., 2010
TRANSPORTERS
MFS6 PBANKA_1304700 Late Yes Kenthirapalan et al., 2016
FUNCTION UNKNOWN
LISP2 PBANKA_1003000 Late Yes Orito et al., 2013
PALM PBANKA_0101100 Very late Yes Haussig et al., 2011
PlasMei2 PY17X_1123700 Late No Dankwa et al., 2016
SPELD PBANKA_0910900 Mid Yes Al-Nihmi et al., 2017
PKGb PBANKA_1008200 Late No Falae et al., 2010
aReferences list only the first report in the respective Plasmodium species.
b Incomplete stage-specific gene knockout.
replication (Figure 1; Mueller et al., 2005a,b; Tarun et al.,
2007).
Immunization studies with one prime and two booster
vaccinations showed complete long-term protection with
P. berghei and P. yoelii 1UIS3 and 1UIS4 GAPs in C57BL/6
and BALB/cJ mice, respectively (Table 2) (Mueller et al.,
2005a,b; Tarun et al., 2007). The study on P. berghei 1UIS4
GAPs established frequent occurrence of breakthrough
infections, i.e., a proportion of animals develop blood
infections during the immunization procedure (Mueller
et al., 2005b). This safety concern needs careful examination
before progression of P. falciparum GAPs to human testing can
take place (Matuschewski, 2013). Notably, the identification of
orthologous genes for UIS3 and UIS4 in P. falciparum has so
far remained elusive, although various ETRAMPs emerge as
potential candidates (Spielmann et al., 2012). To date, only one
P. falciparum ETRAMP has been targeted by reverse genetics
(MacKellar et al., 2010). This protein, termed PfETRAMP 10.3,
apparently performs essential functions during blood infection,
since it remains refractory to targeted deletion and does not
complement the P. yoelii 1UIS4 defects. Accordingly, more
research is needed to identify and target P. falciparum ETRAMPs
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FIGURE 1 | Precision developmental arrests during Plasmodium liver stage maturation by genetically arrested parasites (GAPs). A sporozoite (green)
invades a suitable hepatocyte under simultaneous formation of a replication-competent intracellular organelle, termed parasitophorous vacuole (orange). After
intracellular transformation to round early liver stages, the parasite expands to a single-cell liver stage trophozoite. Early arresting GAPs, e.g., 1UIS3, 1SLARP,
1P36p, stop cell division at this stage. Next, the trophozoite grows in size and replicates and eventually forms a schizont that exceeds the size of the original host cell.
Many GAP lines, such as deletions of the FASII biosynthesis pathway or other apicoplast functions, e.g., 1PALM, arrest after full liver stage maturation. In the last
phase of pre-erythrocytic development, the first generation of erythrocyte-invading stages, termed merozoites are formed and released from the infected hepatocytes
into the blood stream. This step marks the transition from the clinically and diagnostically silent liver phase to the blood infection, which is responsible for all
malaria-related symptoms and pathology. GAPs (right) are listed next to the phase of liver stage development (left) according to their life cycle arrest. Safe and unsafe
GAPs are depicted in black and gray, respectively. Knockouts of the murine and human Plasmodium species are shown on the left and right side, respectively.
to generate this class of GAPs in P. falciparum and test their
vaccine potential in small-scale human trials.
Another first generation GAP line in P. berghei and P. yoelii
are parasites that lack P36p (also termed P52), a member of the
Plasmodium-specific 6-Cys protein family (van Dijk et al., 2005).
Parasites lacking P36p (P52) or its paralog, P36, arrest again early
during liver stage development after completion of sporozoite
transformation (Figure 1) (Ishino et al., 2005; van Dijk et al.,
2005). 1P36p sporozoites transmigrate and invade hepatocytes,
wherein they initiate the formation of a parasitophorous vacuole
membrane (PVM). Although, they start to mature into liver stage
trophozoites, 1P36p parasites suddenly abort this development,
most likely because maintenance and maturation of the PVM are
critically impaired (van Dijk et al., 2005).
Once more, occasional breakthrough infections in mice
inoculated with1P36p sporozoites were observed (vanDijk et al.,
2005). Interestingly, in the1P36p/P36 double knockout parasite
expression of the signature merozoite surface protein 1 (MSP1)
could not be detected, and the mechanism of breakthrough
infections remains unsolved (Ploemen et al., 2012). Targeted gene
deletion of a second member of the 6-Cys family, termed B9,
led to similar early arrest and occasional breakthrough infections
(Annoura et al., 2014).
Since genes of the 6-Cys protein family are remarkably
conserved across Plasmodium species, P. falciparum GAP lines
were generated to show proof of principle of liver stage
attenuation by targeted gene deletion in humanmalarial parasites
(van Schaijk et al., 2008; van Buskirk et al., 2009). However, in
order to advance this approach to clinical testing in humans,
safety is of utmost importance. Accordingly, it remains enigmatic
why a PfGAP based on P52 (P36p) and P36 was selected for a first
phaseI/IIa clinical trial (Spring et al., 2013), despite the alarming
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TABLE 2 | P. berghei and P. yoelii GAPs: long-term immunization studies.
GAPsa Immunization dose (days after priming) Challengeb (days
after last boost)
No. protected/No.
challenged animalsc
References
1 2 3
ETRAMPS
1UIS3 50 k 25 k (34) 25 k (45) 10 k (30) 5/5 (100%) Mueller et al., 2005a
10 k 10 k (34) 10 k (45) 10 k (30) 5/5 (100%)
10 k 10 k (14) 10 k (28) 10 k (60) 4/4 (100%) Tarun et al., 2007
(180) 8/12 (67%)
10 k 10 k (14) − 10 k (30) 4/4 (100%)
1UIS4 50 k 25 k (14) 25 k (28) 50 k (38) 8/8 (100%) Mueller et al., 2005b
10 k 10 k (14) 10 k (28) 50 k (38) 8/8 (100%)
10 k 10 k (14) 10 k (28) 10 k (60) 4/4 (100%) Tarun et al., 2007
(180) 8/8 (100%)
50 k − − 10 k (30) 4/4 (100%)
1UIS3/UIS4 75 k 20 k (7) 20 k (14) 10 k (180) 6/6 (100%) Jobe et al., 2007
10 k 10 k (14) 10 k (28) 10 k (118) 14/14 (100%)
1UIS3/LISP2 50 k 20 k (14) 20 k (28) 10 k (42) 8/8 (100%) Kumar et al., 2016
(102) 8/8 (100%)
6-CYS PROTEINS
1P36p 50 k 20 k (7) 20 k (14) 10 k (30) 5/5 (100%) van Dijk et al., 2005
1P52/P36 10 k 10 k (7) 10 k (14) 10 k (30) 7/7 (100%) Labaied et al., 2007
1B9 50 k 20 k (7) 20 k (14) 10 k (90) 5/5 (100%) van Schaijk et al., 2014a
(180) 9/9 (100%)
(365) 5/11 (45%)
DIFFERENTIATION FACTORS
1SLARP (1SAP1) 50 k 25 k (14) 25 k (28) 10 k (42) 5/5 (100%) Silvie et al., 2008b
(98) 2/5 (40%)
10 k 10 k (14) 10 k (28) 10 k (36) 1/4 (25%)
1 k 1 k (14) 1 k (28) 10 k (36) 0/4 (0%)
10 k 10 k (14) 10 k (28) 10 k (30) 25/25 (100%) Aly et al., 2008
10 k (120) 25/25 (100%)
1 k 1 k (14) 1 k (28) 10 k (30) 10/10 (100%) Butler et al., 2011
1 k 1 k (14) − 10 k (30) 2/10 (20%)
1SLARP/B9 50 k 25 k (7) 25 k (14) 10 k (180) 6/6 (100%) van Schaijk et al., 2014a
1SAP1/P52/P36 10 k 10 k (14) − 10 k (30) 5/5 (100%) Kublin et al., 2017
(180) 5/5 (100%)
FATTY ACID SYNTHESIS PATHWAY
1FabB/F 50 k 50 k (14) 50 k (28) 10 k (210) 8/8 (100%) Butler et al., 2011
10 k 10 k (14) 10 k (28) 10 k (100) 5/5 (100%)
(300) 8/8 (100%)
10 k 10 k (14) 10 k (28) 10 k (30) 8/8 (100%)
1 k 1 k (14) 1 k (28) 10 k (30) 10/10 (100%)
1 k 1 k (14) − 10 k (30) 10/10 (100%)
1G3PAT 10 k 10 k (37) − 10 k (37) 30/30 (100%) Lindner et al., 2014
1G3PDH 10 k 10 k (37) − 10 k (37) 30/30 (100%) Lindner et al., 2014
1PDH-E1-PFOLS 5 k 5 k (25) 5 k (50) 5 k (30) 10/10 (100%) Nagel et al., 2013
OTHER FUNCTIONS
1PALM 10 k 10 k (∼30) − 10 k (∼30) 5/5 (100%) Haussig et al., 2011
(110) 6/7 (86%)
1MFS6 10 k 10 k (9) − 10 k (22) 2/2 (100%) Kenthirapalan et al., 2016
1 k 1 k (9) − 10 k (22) 1/12 (8%)
1PlasMei2 10 k 10 k (35) 10 k (45) 10 k (∼40) 21/21 (100%) Dankwa et al., 2016
aP. berghei and P. yoelii knockout parasite lines are displayed in black and gray, respectively.
bOnly studies where i. v. challenge was performed at least 3 weeks after the last boost are listed.
c Immunizations were performed in the P. berghei-C57BL/6 and P. yoelii-BALB/cJ combinations, respectively.
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preclinical data. As predicted, human trials with Pf1P52/P36 had
to be suspended because of breakthrough infections (Spring et al.,
2013).
A potential, albeit untested, advantage of 6-Cys protein-
based GAPs is enhanced antigen presentation via MHCI on
infected hepatocytes, since maintenance of the parasitophorous
vacuole is impaired (van Dijk et al., 2005). Perhaps even more
important, the propensity to increase apoptosis in 1P36p-
infected hepatocytes (van Dijk et al., 2005) might enhance cross-
priming by dendritic cells (DCs) that phagocytose apoptotic
bodies (Leiriao et al., 2005), although this conjecture remains
controversial (Renia et al., 2006).
Together, the first generation GAPs established that
precise developmental arrests during the first clinically
silent, intrahepatic Plasmodium expansion phase can be
engineered by tailored removal of individual vital genes
from the entire Plasmodium genome (Table 1). These
uniform, genetically defined parasites consistently elicit lasting
protection against sporozoite challenge infections in vaccination
protocols with three consecutive GAP sporozoite inoculations
(Table 2).
GAPs TARGETING LIVER STAGE
DIFFERENTIATION: SAFETY FIRST
The observations of breakthrough blood infections during the
immunization protocol in a proportion of animals (Mueller
et al., 2005b; van Dijk et al., 2005) initiated the search for
candidate Plasmodium genes that are key developmental factors,
for instance transcription factors at the nexus of sporozoite to
liver stage transformation. Such a factor was identified during
the analysis of sporozoite-specific (S) genes (Kaiser et al., 2004).
Targeted gene deletion of this factor, termed S22 or sporozoite
and liver stage asparagine-rich protein (SLARP or SAP1) (Aly
et al., 2008; Silvie et al., 2008b), resulted in a complete arrest
of the parasite at early liver stage development prior to nuclear
division (Figure 1). A novel hallmark of 1SLARP parasites
was the differential down-regulation of many liver stage-specific
mRNAs and their corresponding proteins, including PVM-
resident proteins such as UIS3 and UIS4 (Aly et al., 2008;
Silvie et al., 2008b), suggesting pleiotropic defects as a result of
the absence of a major transcriptional regulator of liver stage
differentiation.
Most importantly, 1SLARP parasites are the first and only
GAPs reported to fulfill all criteria of safe arrest (Aly et al.,
2008; Silvie et al., 2008b). Accordingly, after the safety failure of
Pf1P52/P36, all PfGAPs developed for clinical testing in humans
include the corresponding PfSLARP knockout (Mikolajczak et al.,
2014; van Schaijk et al., 2014a; Kublin et al., 2017). However,
immunization studies showed a lack in long-term protection in
animals immunized with P. berghei 1SLARP parasites, where
only 40% of all animals were protected 3.5 months after
immunization (Table 2) (Silvie et al., 2008b). It is conceivable that
1SLARP parasites display a smaller array of antigens, but this
has to be experimentally tested employing systems immunology
approaches.
Notably, targeting of other key factors important for liver
stage gene expression did not result in a similar complete liver
stage arrest. Deletion of the liver stage-specific transcription
factor of the apetala 2 family, termed AP2-L, only resulted in
a developmental delay (Iwanaga et al., 2012). Knockout of the
eukaryotic initiation factor 2α (eIF2α) kinase (IK2/UIS1), which
is critical for sporozoite latency, and stage-specific knockout of
the corresponding eIF2α-P protein phosphatase 1 (PP1/UIS2),
which is a regulator of protein translation after hepatocyte
invasion, led to incomplete early arrests before and immediately
after hepatocyte invasion (Zhang et al., 2010, 2016). Targeted
deletion of another regulator of sporozoite latency, the RNA-
binding protein PUF2, reproduced the 1IK2/UIS1 phenotype,
again with an unsatisfactory safety profile (Gomes-Santos et al.,
2011; Müller et al., 2011).
In conclusion, immunization data together with the
demonstration of a very early, complete arrest indicate that
1SLARP parasites are comparable to RAS, with the important
distinctions of a precision life cycle arrest in humans (Kublin
et al., 2017) and safe handling of 1SLARP-infected Anopheles
mosquitoes for vaccine production.
LATE ARRESTING GAPs: IMPROVED
IMMUNOGENICITY BUT LACK OF SAFETY
Studies employing co-administration of normal sporozoites and
anti-malarial drugs have consistently shown superior immunity
of late liver stage and/or early blood cycle arrest in murine
malaria models (Belnou et al., 2004; Friesen et al., 2010;
Friesen and Matuschewski, 2011) and small scale human trials
(Roestenberg et al., 2009; Bijker et al., 2013), suggesting that a late
liver stage arrest offers multiple advantages, perhaps including
broader antigen presentation (Borrmann and Matuschewski,
2011). Unexpectedly, antibiotic-induced arrest at the transition
from late liver stages to blood infection leads to better protection
than a later arrest, after a few rounds of blood stage replication,
induced by chloroquine treatment (Friesen and Matuschewski,
2011). This indicates an immune-modulatory effect by infected
red blood cells and potential benefits of a complete arrest at the
liver stage.
Therefore, tailored arrest toward the end of liver stage
maturation was an important third step in GAP vaccine
design. A CAS-based arrest using the antibiotic azithromycin
showed that specific targeting of the Plasmodium apicoplast,
a relict non-photosynthetic plastid organelle, resulted in late
arrest after complete liver stage maturation (Friesen et al.,
2010). Accordingly, two complementary approaches targeting
key factors in the Plasmodium apicoplast led to generation of
late-arrested GAPs and their testing in vaccine studies (Figure 1),
namely deletion of a fatty acid biosynthesis enzyme (Butler et al.,
2011) and a Plasmodium-specific protein of unknown function
(Haussig et al., 2011). In both cases potent protection against
reinfection was reported and superior protection correlated with
extended liver stage maturation.
The fatty acid synthesis II (FASII) pathway produces saturated
fatty acids in the apicoplast. It includes a cyclic reaction
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that catalyzes fatty acid elongation and a large pyruvate
dehydrogenase (PDH) complex that forms acetyl-CoA for the
elongation cycles (Yu et al., 2008). Targeted deletion of an enzyme
of the cyclic reaction, namely trans-2-enoyl-ACP reductase
(FabI), in P. berghei revealed a specific defect during liver
stage maturation (Yu et al., 2008). However, the life cycle
arrest was incomplete and sporozoite inoculations resulted in
substantial breakthrough infections in C57BL/6 mice (Table 1)
(Yu et al., 2008). Accordingly, immunization studies were not
performed.
The liver stage defects of mutants in the FASII biosynthesis
pathway in murine malaria parasites were confirmed in P. yoelii
studies by targeted deletion of 3-oxoacyl-ACP synthase I/II
(FabB/F) and β-hydroxyacyl-ACP dehydratase (FabZ) (Vaughan
et al., 2009). Since breakthrough infections were once more
absent in the P. yoeliimodel testing of1FabB/F parasites as late-
arrested GAPs in vaccination protocols was possible (Table 2)
(Butler et al., 2011). This study reported better protection and
a larger CD8+ T cell response in comparison to 1SAP1 and
RAS parasites. Targeted gene deletion of additional P. yoelii
enzymes of the FASII and the subsequent lipid biosynthesis
pathway resulted in similar arrests in liver schizont maturation
prior to merozoite formation (Pei et al., 2010; Lindner et al.,
2014). The target genes were the E1α and E3 subunits of PDH,
glycerol-3-phosphate acyltransferase (G3PAT), and glycerol-3-
phosphate dehydrogenase (G3PDH) (Figure 1) of which the
latter performed well in vaccine protocols (Table 2).
The previous observation of breakthrough infections in the
first study of a P. berghei FASII pathway knockout (Yu et al.,
2008) was subsequently confirmed (Table 1) (Annoura et al.,
2012; Shears et al., 2017) and strictly limits the results from
studies in P. yoelii. The additional, unexpected finding of
aborted parasite development in mosquitos infected with the
corresponding P. falciparum knockouts (Cobbold et al., 2013;
van Schaijk et al., 2014b) essentially eliminated the possibility to
develop GAP vaccines by targeted deletion of the FASII pathway.
Together, these results also raise the important question, which
prerequisites have to be fulfilled to transfer discoveries from
murine models to PfGAP vaccines.
The second strategy of targeting essential apicoplast functions
to generate late liver stage-arrested parasite lines built upon
bioinformatic prediction of Plasmodium-specific apicoplast
targeted proteins (Haussig et al., 2011). The first target that
satisfied these criteria was P. berghei Plasmodium-specific
apicoplast protein important for liver merozoite formation
(PALM), a protein of unknown function. Targeted deletion of
PALM did not affect parasite growth or apicoplast morphology,
but resulted in an even later arrest after completion of liver
stage development prior to merozoite release (Haussig et al.,
2011). Although, immunizations with1PALM resulted in robust
long-term protection after only two immunizations in the
stringent P. berghei-C57BL/6 model (Table 2), consistent dose-
independent breakthrough infections preclude the translation to
human Plasmodium species, unless this mutant is combined with
an additional knockout that causes a similar life cycle arrest.
Several attempts to target other biochemical pathways within the
apicoplast, including iron-sulfur cluster biogenesis or primary
reactions in heme biosynthesis, did not yield 1PALM-like GAPs
(Haussig et al., 2013, 2014; Rizopoulos et al., 2016).
Additional late arresting candidate genes have been identified;
however, in depth analysis and immunization studies are
often lacking. An interesting case is protein kinase G (PKG),
which is shared across different life cycle stages and already
essential during blood infection, as it plays prominent roles
in merozoite egress and gametogenesis. Since generation of a
1PKG parasite is incompatible with blood infection, a stage-
specific knockout by FLP/FRT recombination in sporozoites was
engineered to study the role(s) in pre-erythryocytic development
(Falae et al., 2010). This analysis revealed a late arrest in liver
stage maturation and wild type breakthrough infections due to
incomplete recombination (Table 1). Immunization studies were
not conclusive since challenge infections were performed only
one week after high dose immunizations. However, the example
of PKG illustrates that a tight late arrested parasite might be
achieved once a suitable liver stage-specific gene at the nexus of
stage conversion is identified.
GAPs WITH MULTIPLE GENE DELETIONS:
SYNERGISTIC OR ANTAGONISTIC?
Development of parasite lines that harbor multiple gene
deletions is likely to increase safety; however, whether synergistic
or antagonistic effects modulate immunogenicity is less
straightforward to predict and likely depends on the selected
knockout combination.
Soon after the first proof-of-principle studies a GAP parasite
line that harbors two consecutive gene deletions, namely 1UIS3
and 1UIS4, was engineered in P. berghei (Jobe et al., 2007).
As expected, 1UIS3/UIS4 parasites displayed a complete arrest
in early liver stages, indicating that vaccine strains harboring
multiple independent gene deletions perform safer than single
knockout GAPs. Importantly, long-term protection against a
high-dose sporozoite challenge infection was complete (Table 2).
In marked contrast, when a double knockout was performed
for the P. berghei paralogs P36p (P52) and P36, which are
neighboring genes and likely arose through gene duplication,
safety was not improved (Annoura et al., 2012), strongly
suggesting that independent genes need to be targeted in
multiple gene knockout strategies. Since1SLARP GAPs lead to a
complete termination of liver stage development (Aly et al., 2008;
Silvie et al., 2008b), they constituted the obvious platform for
combinations with knockouts of the 6-Cys gene family (Figure 1)
(Mikolajczak et al., 2014; van Schaijk et al., 2014a; Kublin et al.,
2017). However, it remains to be shown whether addition of
B9, P36, and/or P36p (P52) knockout provides any additional
benefit beyond perception of additional gene deletions. An
important investigation with combinatorial knockouts will be the
systematic expression profiling of liver stage-specific genes, as
was previously done for 1SLARP parasites (Silvie et al., 2008b).
Such an analysis will provide first insights into the expected
antigenic repertoire displayed by the respective GAPs.
Instead of adding additional gene deletions, which might
not add significantly to vaccine efficacy, combination of a
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gene deletion with transgene expression of additional factors
could amplify antigen presentation during pre-erythrocytic
development. Potential avenues include perforation of the
intracellular niche, i.e., the parasitophorous vacuole, activation
of innate immune sensing pathways, and expression of blood
stage and gametocyte antigens. Such a strategy is exemplified
by the expression of perfringolysin O, a cholesterol-dependent
cytolysin, in P. berghei 1PDH-E1α parasites (Nagel et al., 2013).
Addition of the transgene could substantially reduce, albeit not
completely abolish, breakthrough infections of the single gene
deletion, providing a rationale for further bioengineering efforts
to achieve premature rupture of the PVM. However, a principal
concern in gain-of-function mutants is that parasites containing
mutations in the transgene promoter and other regulatory
elements, which lead to a reduced transgene expression, will
be swiftly selected. Therefore, GAPs that express additional
Plasmodium antigens in order to broaden the immunogenic
repertoire without further reducing parasite fitness might be a
particularly rewarding research direction.
IMMUNE MECHANISMS OF GAPs: THE
CENTRAL ROLE OF EFFECTOR MEMORY
CD8+ T CELLS
Cytolytic, interferon gamma (IFNγ)-secreting CD8+ T cells
were identified early on as the key mediators of protection
after radiation-attenuated sporozoite immunizations (Schofield
et al., 1987; Weiss et al., 1988; Romero et al., 1989). Amongst
all CD8+ T cell subsets, presence of those with an effector
memory phenotype, i.e., CD45RBlo, CD44high, CD62Llo, and
CD122lo consistently correlated with long-lasting protection
(Guebre-Xabier et al., 1999; Berenzon et al., 2003). Studies
employing immunization of β2 microglobulin (β2M) knockout
mice and recognition of a CSP-specific T cell clone by hepatocytes
with a matching MHCI haplotype revealed that liver stage
antigens are presented to the CD8+ T cells via MHCI on the
surface of infected hepatocytes (White et al., 1996; Balam et al.,
2012). Elimination of infected hepatocytes in immunized mice
could be linked to perforin secreting cytotoxic CD8+ T cells
and IFNγ production (Mellouk et al., 1987; Schofield et al.,
1987; Malik et al., 1991; Rodrigues et al., 1993; Sano et al.,
2001). Employing advanced in vivo imaging techniques direct
proximity to antigen-specific CD8+ T cells was shown to be
required for cytolytic killing of Plasmodium-infected hepatocytes
(Cockburn et al., 2013; Kimura et al., 2013). Although, antigen-
specific CD4+ T cells are expected to be central to mount an
effective T cell response, their roles in B cell help to produce
antibodies that inhibit sporozoite attachment and invasion of
the liver is only minor. Antibodies are not essential for vaccine-
induced protection, and protective CD8+ T cell responses can be
mounted without CD4+ help (Schofield et al., 1987; Rodrigues
et al., 1993).
Based on the insights from studies with irradiated sporozoites,
CD8+ T cell-dependent elimination most likely is the immune
effector mechanism in GAP-immunized animals. Indeed, a
study employing P. berghei 1UIS3 parasites showed that
immunizations of B and T cell-deficient rag1−/− and IFNγ−/−
knockout mice failed to induce protection, confirming the central
role of adaptive immune responses leading to IFNγ production in
vaccine-induced immunity (Mueller et al., 2007). Immunizations
of B cell-deficient mice and common laboratory mice after
depletion or adoptive transfer of CD4+ and CD8+ T cells fully
corroborated the central importance of CD8+ T cells, but neither
of antibodies nor of CD4+ T cells. Of note, primaquine treatment
results in efficient cure of liver stage parasites and reversed
1UIS3-mediated protection (Mueller et al., 2007). This is in
perfect agreement with the requirement for parasite persistence
as metabolically active, cell cycle arrested intra-hepatic stages
in order to maintain long-term protection (Scheller and Azad,
1995).
Another early study demonstrated the central role of CD8+
T cells, and particularly IFNγ-secreting effector memory cells, in
protection induced by a P. berghei1UIS3/UIS4 double knockout
parasite line (Jobe et al., 2007). Immunization of β2m−/− mice,
which are deficient in MHCI expression and CD8+ T cells,
abrogated vaccine efficacy. The direct comparison to RAS showed
that both immunization strategies induce similar immune
responses, but GAP-immunized animals displayed consistently
higher levels of IFNγ-secreting effector memory cells (Jobe et al.,
2007). Accordingly, it is conceivable that the insights gained from
RAS immunizations can be extrapolated at least to 1UIS3/UIS4
GAP vaccines.
The findings obtained with P. berghei GAPs were fully
supported by a study reporting that depletion of CD8+
T cells, but neither CD4+ T cells nor IgG1 antibodies,
abolished protection by P. yoelii 1UIS3 or 1UIS4 parasite
lines (Tarun et al., 2007). Notably, CD8+ T cells from
P. yoelii GAP immunized mice induce apoptosis of infected,
in vitro cultured hepatocytes by contact dependent, perforin-
mediated cytotoxic killing, with only partial involvement of IFNγ
(Trimnell et al., 2009). Short-lived CD11ahi, CD62Llo, CD44hi
antigen-experienced effector CD8b+ T cells, which also express
CD11c, expanded swiftly after one immunization with P. yoelii
1UIS4 sporozoites (Cooney et al., 2013). Furthermore, these
cells are KLRG1+CD127− terminal effector cells, which upon
restimulation with infected hepatocytes secrete IFNγ, TNF, and
IL-2 and express CD107a and perforin. Late-arresting P. yoelii
GAPs induced larger CD8+ T cell responses in comparison
to RAS, and the CD8αloCD11ahi effector memory phenotype,
characterized by low expression levels of CD27, CD62L, and
CD127, was increased; however, this study was done in C57BL/6
mice only (Butler et al., 2011).
While the cellular mechanisms that lead to elimination
of infected hepatocytes after immunization are relatively well
understood, the target epitopes displayed by infected hepatocytes
remain less clear (Hafalla et al., 2011). There is growing evidence
that a combination of epitopes rather than a single protective
antigen correlates with vaccine-induced protection (Grüner et al.,
2007; Hafalla et al., 2013). The present list of pre-erythrocytic T
cell epitopes in H2-Kd-restricted BALB/cJ and H2-Kb-restricted
C57BL/6 mice remains short (Romero et al., 1989; Hafalla et al.,
2013; Murphy et al., 2013; Lau et al., 2014; Müller et al., 2017).
The few immunogenic epitopes identified thus far underscore
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the fundamental differences of immunity elicited by eukaryotic
pathogens in comparison to viruses and bacteria (Hafalla et al.,
2013).
The mechanisms leading to efficient priming of effector
immune responses against pre-erythrocytic parasites are still
incompletely understood. Efficient priming almost certainly
requires cross-presentation by dendritic cells (DCs) and is most
likely a combination of DC-mediated antigen presentation in
different organs, including skin-draining lymph nodes, spleen,
and liver (Sano et al., 2001; Chakravarty et al., 2007; Cockburn
et al., 2011; Balam et al., 2012). Most studies focused on the
CSP epitope, which is abundantly expressed on the sporozoite
surface and only recognized in H2-Kd -restricted BALB/cJ mice
(Romero et al., 1989; Sano et al., 2001; Chakravarty et al., 2007;
Balam et al., 2012). Whether GAPs aborting development at the
trophozoite stage or later present additional antigens explaining
superior CD8+ T cell responses remains elusive.
TOWARD UNIFIED GUIDELINES FOR
TRANSLATIONAL GAP RESEARCH
There are currently no rules established for GAP development
in P. falciparum; however, defining a set of requirements that
need to be fulfilled before moving on to P. falciparum studies
would significantly decrease odds of clinical trial failures. An
obvious criterion from murine malaria models, i.e., P. berghei
and P. yoelii, is complete liver stage arrest in a large number
of animals employing both murine models simultaneously.
Humanized mouse models and primary human hepatocytes can
provide preliminary indications on developmental arrest in the
liver and, thus, potential safety concerns of a P. falciparum
GAP vaccine candidate. However, these test systems might
not provide the level of stringency necessary to predict break-
through infections, which are presently best captured in pre-
clinical tests in large groups of mice. In order to develop potent
P. falciparum GAPs beyond early arresting 1SLARP mutants,
multiple independent gene deletions, ideally in unrelated
physiological processes and in different cellular compartments,
need to be considered.
Another desirable standard is robust long-term immunity
against challenge infection. Identifying the correct parasite/host
combination is important to draw valid conclusions from
immunization experiments (Matuschewski, 2013). The
P. berghei-C57BL/6 combination remains the most robust
vaccine model to date, whereas immunizations using P. yoelii
mutants in BALB/c mice are only of modest predictive value,
since protection is easily achieved in this model. Other
combinations, such as P. berghei and BALB/c mice, are
invalid because of refractoriness of particular combinations
of mouse strains and infections with certain murine malaria
sporozoites (Scheller et al., 1994). This notion is illustrated
in immunizations with P. berghei 1P36p sporozoites, where
only one immunization dose in an inappropriate host strain,
BALB/c mice, resulted in complete protection up to 3 months
after immunization (van Dijk et al., 2005). Immunization with
P. yoelii 1P36p/P36 parasites also induced sterile protection
in BALB/c mice after a single injection (Labaied et al., 2007);
however, such protection in C57BL/6 mice was only elicited
after three rounds of immunization (van Dijk et al., 2005).
One important immunological difference is that protection in
the P. yoelii-BALB/c model largely depends on the immune-
dominant CD8+ T cell epitope of CSP. In marked contrast,
T cell responses in the P. berghei-C57BL/6 model are likely
multifactorial (Hafalla et al., 2011, 2013), which closely mimics
infections in human populations with a large range of MHCI
haplotypes and only infrequent CSP–specific CD8+ T cell
responses (Offeddu et al., 2012). The recent evaluation of
Grammomys dolichurus, an Afrotropical arboreal rodent, which
naturally harbors rodent Plasmodium infections, as a model to
study pre-erythrocytic vaccine strategies will be an important
addition for preclinical evaluation of safety and immunogenicity
of GAP vaccines (Conteh et al., 2017). In good agreement with
the data from murine Plasmodium models, the natural host is
highly susceptible to P. berghei sporozoite induced infections
and multiple high immunization doses are required for robust
protection (Conteh et al., 2017).
Together, comparative studies on vaccine efficacy
should include the P. berghei-C57BL/6 model (Friesen and
Matuschewski, 2011), to better define long-term protection
against re-challenges. We propose that a GAP vaccine line
should be evaluated for vaccine safety and immunogenicity in a
two-step preclinical process before advancing to human trials.
First, comparative evaluation of the candidate P. berghei and
P. yoelii GAP lines in the respective mouse strains, C57BL/6
and BALB/c, will pre-select GAPs that are completely arrested
upon high dose sporozoite inoculations and elicit long-lasting
(>30 days) sterile immunity. Second, confirmation of safety
and immunogenicity of the P. berghei GAP line in G. dolichurus
immunization and challenge study provide an evidence-based
rationale for translation to P. falciparum GAP trials.
ROADBLOCKS TOWARD TRANSLATION
OF GAPs
Intravenous injections are the preferential route of vaccine
administration in mouse models; however, in real life this
is inapplicable. Pediatric vaccines are exclusively administered
either by intramuscular syringe injection or orally. It is evident
that a malaria vaccine must adhere to the same safe routes
of administration. Alternative methods that are used in drug
delivery, such as intradermal, intravenous, or intraperitoneal
injections, are unreasonable for a malaria vaccine to be delivered
in resource-poor health infrastructures, because of the risks
associated with these routes of administration, except under
physician’s care.
Plasmodium sporozoites apparently lack the ability to
transmigrate through muscle or fat tissue. Accordingly, after
intradermal, intramuscular, subcutaneous, or intraperitoneal
injection only a very small proportion of sporozoites reach
a blood vessel, resulting in reduced liver infection. This was
confirmed in human volunteer studies, where intramuscular
or intradermal syringe injections of cryopreserved sporozoites
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showed substantial delays in blood infections and high doses were
required to consistently induce blood infections (Shekalaghe
et al., 2014; Gómez-Pérez et al., 2015). As expected, protection
after immunizations via these routes was negligible both in the
P. berghei model and in volunteer studies with P. falciparum
sporozoites (Epstein et al., 2011; Nganou-Makamdop et al., 2012).
Thus, development of a GAP vaccine that can be administered in
the muscle is a principal hurdle that needs to be overcome by
bioengineering efforts.
The necessity for booster immunizations remains another
critical limitation, which is unlikely to be removed. However, a
reduction of the vaccine doses would facilitate the distribution of
a malaria vaccine considerably. A better understanding of how to
best amplify an initial protective CD8+ T cell response toward a
sustained effector-memory T cell response will be essential. It is
conceivable that timing of antigen expression is important, and
the temporal dynamics of expansion and contraction of antigen-
specific T cells need to be analyzed to inform vaccine protocols
(Hafalla et al., 2013; Murphy et al., 2013; Billman et al., 2016).
Cryopreservation of sporozoites is so far the only way of
efficiently preserving the infectivity of attenuated sporozoites,
posing huge logistic constraints. Thus, development of a vaccine
formulation, which is stable under cooled conditions or, ideally,
at ambient temperature and induces long-term protection,
remains a critical bioengineering milestone. Plasmodium
sporozoites are particularly sensitive to environmental
conditions, and it remains entirely speculative whether an
appropriate preservation process can be implemented. A GAP
vaccine formulation might be further improved by addition of
an adjuvant; however, no examples exist yet for live attenuated
Plasmodium vaccines.
OUTLOOK
Building on the success of live attenuated, metabolically active
RAS, genetic engineering of liver stage-arrested parasites offers
unprecedented opportunities to develop a precision malaria
vaccine. Comparative studies with GAPs that display distinct
temporal arrests during liver stage maturation provide a
foundation for systems immunology approaches, which might
in turn lead to a better mechanistic understanding of immune
effector mechanisms that contribute to lasting protection against
re-infection. Ultimately, evidence-based design of safe and
effective whole sporozoite P. falciparum and P. vivax vaccines
involves major research investments in preclinical murine
malaria models before translation to the human parasite is
warranted. Proper design of human clinical trials with predictive
power for vaccine safety, negligible adverse events, and vaccine
efficacy in young children living in very diverse tropical countries
remains very challenging.
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